Association of ankylosing spondylitis with the risk of cancer: a meta-analysis of cohort studies.

IF 4.7 2区医学 Q1 RHEUMATOLOGY

Rheumatology Pub Date : 2025-02-01 DOI:10.1093/rheumatology/keae294

Lulin Yu, Yici Yan, Wenjing Liu, Siyu Huang, Leitao Sun, Shanming Ruan

{"title":"Association of ankylosing spondylitis with the risk of cancer: a meta-analysis of cohort studies.","authors":"Lulin Yu, Yici Yan, Wenjing Liu, Siyu Huang, Leitao Sun, Shanming Ruan","doi":"10.1093/rheumatology/keae294","DOIUrl":null,"url":null,"abstract":"Objectives: The potential impact of ankylosing spondylitis (AS) on cancer risk remains unclear. This study seeks to investigate the relationship between AS and different types of cancers.Methods: A literature search on PubMed, EMBASE and Cochrane Library up to 10 July 2023 was conducted. Two investigators selected eligible studies and extracted relevant data. The study used the random-effects model to explore the causality between AS and cancer, utilizing relative risk (RR) as a measure for the study.Results: A total of 20 cohorts with >330 000 participants were included. The pooling analysis shows AS being associated with a higher risk of cancers (RR = 1.16, 95% CI: 1.07-1.26, P = 0.001, I2 = 70.60%). In the subgroup analysis, AS has a higher cancer risk in Asia, but this association is not significant in Europe. Individual investigations indicate that AS is associated with an increased risk of bone cancer (RR = 3.41, 95% CI: 1.45-7.99, P = 0.005, I2 = 0.00%), thyroid gland cancer (RR = 1.76, 95% CI: 1.29-2.40, P < 0.001, I2 = 13.70%), multiple myeloma (RR = 1.74, 95% CI: 1.42-2.15, P < 0.001, I2 = 27.20%), leukaemia (RR = 1.52, 95% CI: 1.27-1.82, P < 0.001, I2 = 0.00%), kidney cancer (RR = 1.45, 95% CI: 1.08-1.94, P = 0.014, I2 = 0.00%), prostate cancer (RR = 1.43, 95% CI: 1.17-1.74, P < 0.001, I2 = 82.80%) and non-Hodgkin's lymphoma (RR = 1.42, 95% CI: 1.17-1.73, P < 0.001, I2 = 0.00%). However, there is no significant correlation with connective tissue cancer, brain cancer, testicular and other male cancers, bladder cancer, female cancers, skin cancer, and cancers of the digestive system and respiratory system.Conclusion: AS appears to be related to cancer development. The results highlighted the necessity for large-scale studies, considering influencing factors such as AS course, medication histories and potential biases when examining cancer risk.","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":"440-454"},"PeriodicalIF":4.7000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/rheumatology/keae294","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: The potential impact of ankylosing spondylitis (AS) on cancer risk remains unclear. This study seeks to investigate the relationship between AS and different types of cancers.

Methods: A literature search on PubMed, EMBASE and Cochrane Library up to 10 July 2023 was conducted. Two investigators selected eligible studies and extracted relevant data. The study used the random-effects model to explore the causality between AS and cancer, utilizing relative risk (RR) as a measure for the study.

Results: A total of 20 cohorts with >330 000 participants were included. The pooling analysis shows AS being associated with a higher risk of cancers (RR = 1.16, 95% CI: 1.07-1.26, P = 0.001, I2 = 70.60%). In the subgroup analysis, AS has a higher cancer risk in Asia, but this association is not significant in Europe. Individual investigations indicate that AS is associated with an increased risk of bone cancer (RR = 3.41, 95% CI: 1.45-7.99, P = 0.005, I2 = 0.00%), thyroid gland cancer (RR = 1.76, 95% CI: 1.29-2.40, P < 0.001, I2 = 13.70%), multiple myeloma (RR = 1.74, 95% CI: 1.42-2.15, P < 0.001, I2 = 27.20%), leukaemia (RR = 1.52, 95% CI: 1.27-1.82, P < 0.001, I2 = 0.00%), kidney cancer (RR = 1.45, 95% CI: 1.08-1.94, P = 0.014, I2 = 0.00%), prostate cancer (RR = 1.43, 95% CI: 1.17-1.74, P < 0.001, I2 = 82.80%) and non-Hodgkin's lymphoma (RR = 1.42, 95% CI: 1.17-1.73, P < 0.001, I2 = 0.00%). However, there is no significant correlation with connective tissue cancer, brain cancer, testicular and other male cancers, bladder cancer, female cancers, skin cancer, and cancers of the digestive system and respiratory system.

Conclusion: AS appears to be related to cancer development. The results highlighted the necessity for large-scale studies, considering influencing factors such as AS course, medication histories and potential biases when examining cancer risk.

查看原文本刊更多论文

强直性脊柱炎与癌症风险的关系：队列研究荟萃分析。

目的：强直性脊柱炎（AS）对癌症风险的潜在影响仍不清楚。本研究旨在调查强直性脊柱炎与不同类型癌症之间的关系：方法：对截至 2023 年 7 月 10 日的 PubMed、Embase 和 Cochrane 图书馆进行文献检索。两名研究人员选择了符合条件的研究并提取了相关数据。研究采用随机效应模型来探讨强直性脊柱炎与癌症之间的因果关系，并以相对风险（RR）作为研究的衡量标准：结果：共纳入了 20 项队列研究，参与者超过 33 万人。汇总分析显示，强直性脊柱炎与较高的癌症风险相关（RR = 1.16，95% CI : 1.07-1.26，p= 0.001，I2=70.60%）。在亚组分析中，强直性脊柱炎在亚洲的癌症风险较高，但在欧洲这种关联并不显著。个别调查显示，强直性脊柱炎与骨癌（RR = 3.41，95% CI : 1.45-7.99，p= 0.005，I2=0.00%）、甲状腺癌（RR = 1.76，95% CI : 1.29-2.40，p< 0.001，I2=13.70%）、多发性骨髓瘤（RR = 1.74，95% CI : 1.42-2.15，p< 0.001，I2=27.20%）、白血病（RR = 1.52，95% CI : 1.27-1.82，p< 0.001，I2=0.00%）、肾癌（RR = 1.45，95% CI : 1.08-1.94，p= 0.014，I2=0.00%）、前列腺癌（RR = 1.43，95% CI : 1.17-1.74，p< 0.001，I2=82.80%）和非霍奇金淋巴瘤（RR = 1.42，95% CI : 1.17-1.73，p< 0.001，I2=0.00%）。然而，强直性脊柱炎与结缔组织癌、脑癌、睾丸癌和其他男性癌症、膀胱癌、女性癌症、皮肤癌以及消化系统和呼吸系统癌症没有明显的相关性：结论：强直性脊柱炎似乎与癌症的发生有关。结论：强直性脊柱炎似乎与癌症的发生有关。研究结果表明，有必要进行大规模研究，并在研究癌症风险时考虑强直性脊柱炎病程、用药史和潜在偏差等影响因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Rheumatology 医学-风湿病学

CiteScore

9.40

自引率

7.30%

发文量

1091

审稿时长

2 months

期刊介绍： Rheumatology strives to support research and discovery by publishing the highest quality original scientific papers with a focus on basic, clinical and translational research. The journal’s subject areas cover a wide range of paediatric and adult rheumatological conditions from an international perspective. It is an official journal of the British Society for Rheumatology, published by Oxford University Press. Rheumatology publishes original articles, reviews, editorials, guidelines, concise reports, meta-analyses, original case reports, clinical vignettes, letters and matters arising from published material. The journal takes pride in serving the global rheumatology community, with a focus on high societal impact in the form of podcasts, videos and extended social media presence, and utilizing metrics such as Altmetric. Keep up to date by following the journal on Twitter @RheumJnl.